Meeting
2021 ASCO Annual Meeting
A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials.
Authors
Alberto Hernando-Calvo
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Alberto Hernando-Calvo , Abdulazeez Salawu , Marc Oliva Bernal , Daniel Vilarim Araujo , Zhihui (Amy) Liu , Rachel Chen , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2648)
DOI
10.1200/JCO.2021.39.15_suppl.2648
Abstract #
2648
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I clinical trial of stereotactic body radiotherapy with atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
First Author: Timothy J Brown
Poster
2013 ASCO Annual Meeting
Novel toxicity endpoint for dose-finding designs evaluating molecularly targeted agents (MTA).
First Author: Monia Ezzalfani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
FusionVAC22_01: A phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion.
First Author: Michael Bitzer
Poster
2023 ASCO Annual Meeting
Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trials.
First Author: Avina Rami